when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Fosamax Plus D

drug

(alendronate sodium + cholecalciferol)

Marketedupdated 3mo ago

by Organon USA LLC

Approved

community read0 votes

🐶 often sniffed alongside

top 5

drugFOSAMAX36 co-mentions · 18 sources
drugFOSAMAX PLUS D36 co-mentions · 18 sources
tagApproval36 co-mentions · 18 sources
drugALENDRONATE SODIUM18 co-mentions · 18 sources
tagSmall Molecule18 co-mentions · 18 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

all catalysts(18)

approval · 18

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

$OGN13.71-0.04%

FOSAMAX PLUS D (ALENDRONATE SODIUM) — FDA approval

(alendronate sodium + cholecalciferol)

view all 18 catalysts →

News(0)

no news has mentioned this drug yet

brand

Fosamax Plus D

generic

(alendronate sodium + cholecalciferol)

MOA

12.1 Mechanism of Action Alendronate Sodium Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [ 3 H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined 6 and 49 days after [ 3 H]alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover (i.e., the number of sites at which bone is remodeled). In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass. Cholecalciferol Vitamin D 3 is produced in the skin by photochemical conversion of 7-dehydrocholesterol to previtamin D 3 by ultraviolet light. This is followed by non-enzymatic isomerization to vitamin D 3 . In the absence of adequate sunlight exposure, vitamin D 3 is an essential dietary nutrient. Vitamin D 3 in skin and dietary vitamin D 3 (absorbed into chylomicrons) is converted to 25-hydroxyvitamin D 3 in the liver. Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D 3 (calcitriol) in the kidney is stimulated by both parathyroid hormone and hypophosphatemia. The principal action of 1,25-dihydroxyvitamin D 3 is to increase intestinal absorption of both calcium an

indication

Osteoporosis

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 7m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?